ReviewFrontiers in immunology2022
Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment.
Kyriakos A Kirou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this paperpooled itcites it